Cancer immunotherapy has ushered in a transformative era in oncology, offering unprecedented promise and opportunities. Despite its remarkable breakthroughs, the field continues to grapple with the persistent challenge of treatment resistance. This resistance not only undermines the widespread efficacy of these pioneering treatments, but also underscores the pressing need for further research. Our exploration into the intricate realm of cancer immunotherapy resistance reveals various mechanisms at play, from primary and secondary resistance to the significant impact of genetic and epigenetic factors, as well as the crucial role of the tumor microenvironment (TME). Furthermore, we stress the importance of devising innovative strategies to counteract this resistance, such as employing combination therapies, tailoring immune checkpoints, and implementing real-time monitoring. By championing these state-of-the-art methods, we anticipate a paradigm that blends personalized healthcare with improved treatment options and is firmly committed to patient welfare. Through a comprehensive and multifaceted approach, we strive to tackle the challenges of resistance, aspiring to elevate cancer immunotherapy as a beacon of hope for patients around the world.
癌症免疫疗法已引领肿瘤学进入一个变革时代，展现出前所未有的前景与机遇。尽管取得了显著突破，该领域仍持续面临治疗耐药性这一严峻挑战。这种耐药性不仅削弱了这些开创性疗法的广泛疗效，更凸显了深化研究的迫切需求。我们对癌症免疫疗法耐药性复杂机制的探索揭示了多种作用机理，包括原发性与继发性耐药、遗传与表观遗传因素的重要影响，以及肿瘤微环境的关键作用。此外，我们强调制定创新策略以克服耐药性的重要性，例如采用联合疗法、定制免疫检查点方案及实施实时监测。通过倡导这些前沿方法，我们期待建立一种将个性化医疗与优化治疗方案相结合的新范式，并坚定致力于提升患者福祉。通过全面多元的研究路径，我们致力于攻克耐药性难题，矢志将癌症免疫疗法打造为全球患者希望的灯塔。
Navigating the Immune Maze: Pioneering Strategies for Unshackling Cancer Immunotherapy Resistance
肿瘤(癌症)患者之家